Skip to main content
Fig. 4 | Experimental Hematology & Oncology

Fig. 4

From: Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed/refractory ALL

Fig. 4

CD8+ and CD4+ T-cell expansion in responding patients. Patients were stratified into responders (blue) and nonresponders (red) based on CR/CRh response within the first two treatment cycles. Box plots depicting the cell counts of all evaluable patients are shown for CD8+ T cells (a), naïve CD8+ T cells (b), memory CD8+ T cells (c), CD4+ T cells (d), naïve CD4+ T cells (e), and memory CD4+ T cells (f). Black line median counts; plus sign mean counts; circle outlying value. Boxes extend from the 25th to 75th percentile, with bars extending to the minimum and maximum values within 1.5 times the interquartile range (difference between the 25th and 75th percentile). Corresponding patient numbers are shown in Additional file 4

Back to article page